Cardiovascular · AnginaRegulatory Approvalregulatorymid-term

FDA Grants Approval for Nitrogycerin ANDA214565 by Padagis Israel

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/12/2026, 6:02:50 AM

Assessment confidence: 60% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Nitrogycerin ANDA214565 by Padagis Israel signifies a new entrant in the cardiovascular market, potentially intensifying competition. Pharma strategy teams must evaluate the implications for their existing products and market positioning. Regulatory context from FDA (FDA AP — NITROGLYCERIN (ORIG)) supports the near-term read. Assessment grounded in 11 ranked evidence items (3 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and pricing strategies for similar products. The strongest clinical anchor is Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using Low Specific Absorption Rate (SAR) Scanner System (ClinicalTrials.gov), mechanism alignment (io ). In Cardiovascular · Angina, 2 regulatory and 0 competitive items passed relevance filtering for Nitroglycerin.

Competitive Pressure

The most relevant competitive pressure comes from This approval may increase competition in the cardiovascular market for angina treatments, particularly against existing nitroglycerin products..

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — NITROGLYCERIN (ORIG) (FDA). Entity match (nitroglycerin); Regulatory pathway relevance (nda). The approval indicates a shift in the regulatory landscape for cardiovascular drugs, necessitating ongoing compliance monitoring and potential adjustments in strategy for similar products.

Key Risks

Elevated medium regulatory exposure for Nitroglycerin could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose) could weigh on Nitroglycerin through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Increased competition may pressure pricing and market share for existing nitroglycerin products, impacting revenue streams for current market players.
Upside for Nitroglycerin may improve if Dose-Response to Resistance Exercise on Cardiovascular Health (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of this approval on market share and pricing strategies for similar products.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and any subsequent pricing strategies from Padagis Israel.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — NITROGLYCERIN (ORIG)
FDAhigh relevance
Entity match (nitroglycerin); Regulatory pathway relevance (nda)
FDA document
View source
FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source

Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using Low Specific Absorption Rate (SAR) Scanner System
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Dose-Response to Resistance Exercise on Cardiovascular Health
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Shaping Community-based Pathway to Improve TB Surveillance Among African and Hindustan Immigrants Experiencing Vulnerabilities
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

No evidence in this category.

Optimizing estradiol serum levels for optimal skeletal and cardiovascular health during transdermal menopausal hormone therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of different caffeine doses on fat oxidation and cardiovascular response during exercise at FATmax in overweight/obese female college students.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Nitroglycerin

Commercial impact

medium

Increased competition may pressure pricing and market share for existing nitroglycerin products, impacting revenue streams for current market players.

Regulatory impact